In Vivo Characterization of a Novel 𝜸-Secretase Inhibitor SCH 697466 in Rodents and Investigation of Strategies for Managing Notch-Related Side Effects

Figure 2

Aβ40 levels expressed as a percent of vehicle in plasma, cortex, and CSF following acute administration of SCH 697466 to (a) rats, (b) TgCRND8 mice, and (c) nontransgenic B6C3F1 mice. For the TgCRND8 studies (b) CSF was not collected in the 6 hr study and 3 mg/kg SCH 697466 was not included in the 3 hr study. ^∗𝑃<0.02 versus vehicle, Dunnett post hoc test.

(a)

(b)

(c)